Briefing
LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses
Adjuvant durvalumab did not improve OS versus placebo in any prespecified analysis group (all-randomized HR 1.02, 95% CI 0.84-1.25; PD-L1 TC >=25% and EGFR/ALK-negative HR 0.98). MRD positivity was strongly prognostic for worse OS in the placebo arm (HR 6.50 to 8.74 across groups). Durvalumab improved OS among MRD-positive, EGFR/ALK-negative patients with PD-L1 TC >=25% (HR 0.30, 95% CI 0.11-0.80; P=0.011; n=29) and PD-L1 TC >=1% (HR 0.49, P=0.024; n=55); treatment-by-MRD interaction P values were all <0.05.
- Design: LBA
- n: 1,415 randomized; MRD available in 1,131 (80%), of whom 116 (10%) were positive; median follow-up 81 months
- Assay: Invitae Personalized Cancer Monitoring (tumor-informed), tested on plasma at randomization